Cargando…
Combination Therapies with Kinase Inhibitors for Acute Myeloid Leukemia Treatment
Targeting kinase activity is considered to be an attractive therapeutic strategy to overcome acute myeloid leukemia (AML) since aberrant activation of the kinase pathway plays a pivotal role in leukemogenesis through abnormal cell proliferation and differentiation block. Although clinical trials for...
Autor principal: | Takahashi, Shinichiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297912/ https://www.ncbi.nlm.nih.gov/pubmed/37367084 http://dx.doi.org/10.3390/hematolrep15020035 |
Ejemplares similares
-
Current findings for recurring mutations in acute myeloid leukemia
por: Takahashi, Shinichiro
Publicado: (2011) -
Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy
por: DeAngelo, D J
Publicado: (2012) -
Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications
por: Takahashi, Shinichiro
Publicado: (2011) -
Checkpoint Inhibitors in Acute Myeloid Leukemia
por: Damiani, Daniela, et al.
Publicado: (2023) -
HDAC Inhibitors in Acute Myeloid Leukemia
por: San José-Enériz, Edurne, et al.
Publicado: (2019)